New antibody BCD-261 put to the test in healthy volunteers
Knowledge-focused
Ongoing
This early-stage trial is testing a new drug called BCD-261 in 48 healthy Chinese volunteers aged 18 to 45. The goal is to check if it is safe and how the body processes it. No treatment benefit is expected; this study is purely about safety and dosing.
Phase: PHASE1 • Sponsor: SPH-BIOCAD (HK) Limited • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC